Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues
S Salemme, A Ancidoni, N Locuratolo… - Expert Review of …, 2023 - Taylor & Francis
Introduction Alzheimer's disease (AD) is a major global public health challenge. To date, no
treatments have been shown to stop the underlying pathological processes. The cerebral …
treatments have been shown to stop the underlying pathological processes. The cerebral …
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
J Beveridge, E Kaniecki, A Naidu… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying
treatments for Alzheimer disease to have received FDA-approval. There are three different …
treatments for Alzheimer disease to have received FDA-approval. There are three different …
[PDF][PDF] Amyloid-β-targeted therapies for Alzheimer's disease: currently and in the future
H Cai, X Fu, S Quan, Z Ren, C Chu… - Ageing Neurodegener …, 2023 - researchgate.net
Alzheimer's disease (AD) is common and devastating. However, current symptomatic
treatments are unable to alter the progression of the disease. Fortunately, many ongoing …
treatments are unable to alter the progression of the disease. Fortunately, many ongoing …
Clinical management in Alzheimer's disease in the era of disease-modifying therapies
MH Guo, SN Vaishnavi - Current Treatment Options in Neurology, 2023 - Springer
Purpose of review Discuss emerging anti-amyloid disease-modifying therapies for
Alzheimer's disease (AD) and outline how these therapies will change our clinical …
Alzheimer's disease (AD) and outline how these therapies will change our clinical …
Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis
PURPOSE We conducted a meta-analysis to evaluate clinically meaningful benefits and
harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia …
harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia …
Current status of amyloid-targeting immunotherapies for Alzheimer's disease
GT Tabor, DM Holtzman - Science translational medicine, 2023 - science.org
Current status of amyloid-targeting immunotherapies for Alzheimer’s disease | Science
Translational Medicine news careers commentary Journals Science Science brought to you …
Translational Medicine news careers commentary Journals Science Science brought to you …
[HTML][HTML] Progress in the Treatment of Alzheimer's Disease Is Needed–Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators
F Jessen, MG Kramberger, D Angioni… - The Journal of …, 2024 - Springer
Abstract β-amyloid-targeting antibodies represent the first generation of effective causal
treatment of Alzheimer's disease (AD) and can be considered historical research milestones …
treatment of Alzheimer's disease (AD) and can be considered historical research milestones …
Anti‐amyloid antibody treatments for Alzheimer's disease
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's
disease directed against amyloid‐β. This is a joint statement of the European Association of …
disease directed against amyloid‐β. This is a joint statement of the European Association of …
Anti-amyloid antibody therapies in Alzheimer's disease
After years of failed attempts to develop a disease-modifying therapy for Alzheimer's
disease, consistent evidence in support of clinical efficacy was finally presented for a …
disease, consistent evidence in support of clinical efficacy was finally presented for a …
[HTML][HTML] Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics
J Cummings - Drugs, 2023 - Springer
Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …
相关搜索
- alzheimer's disease monoclonal antibodies
- health issues monoclonal antibodies
- alzheimer's disease anti amyloid
- outlook for the future monoclonal antibodies
- alzheimer's disease health issues
- alzheimer's disease clinical management
- meta analysis alzheimer disease
- meta analysis monoclonal antibodies
- antibody treatments anti amyloid